Skip to main content

Advertisement

SpringerLink
Log in

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Earlier studies have shown that modification of the octapeptide octreotide in positions 3 and 8 may result in compounds with increased somatostatin receptor affinity that, if radiolabelled, display improved uptake in somatostatin receptor-positive tumours. The aim of a recent research study in our laboratory was to employ the parallel peptide synthesis approach by further exchanging the amino acid in position 3 of octreotide and coupling the macrocyclic chelator DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to these peptides for labelling with radiometals like gallium-67 or -68, indium-111, yttrium-90 and lutetium-177. The purpose was to find radiopeptides with an improved somatostatin receptor binding profile in order to extend the spectrum of targeted tumours. A first peptide, [111In,90Y-DOTA]-1-Nal3-octreotide (111In,90Y-DOTA-NOC), was isolated which showed an improved profile. InIII-DOTA-NOC exhibited the following IC50 values (nM) when studied in competition with [125I][Leu8, d-Trp22, Tyr25]somatostatin-28 (values for YIII-DOTA-NOC are shown in parentheses): sstr2, 2.9±0.1 (3.3±0.2); sstr3, 8±2 (26±1.9); sstr5, 11.2±3.5 (10.4±1.6). Affinity towards sstr1 and 4 was very low or absent. InIII-DOTA-NOC is superior to all somatostatin-based radiopeptides having this particular type of binding profile, including DOTA-lanreotide, and has three to four times higher binding affinity to sstr2 than InIII,YIII-DOTA-Tyr3-octreotide (InIII,YIII-DOTA-TOC). In addition, [111In]DOTA-NOC showed a specific and high rate of internalization into AR4-2J rat pancreatic tumour cells which, after 4 h, was about two times higher than that of [111In]DOTA-TOC and three times higher than that of [111In]DOTA-octreotide ([111In]DOTA-OC). The internalized radiopeptides were externalized intact upon 2 h of internalization followed by an acid wash. After 2–3 h of externalization a plateau is reached, indicating a steady-state situation explained by reactivation of the receptors followed by re-endocytosis. Biodistribution studies in CA 20948 tumour-bearing rats showed rapid clearance from all sstr-negative tissues except the kidneys. At 4 h the uptake of [111In]DOTA-NOC in the tumour and sstr-positive tissues, such as adrenals, stomach and pancreas, was three to four times higher than that of [111In]DOTA-TOC. Differential blocking studies indicate that this is at least partially due to the uptake mediated by sstr3 and sstr5. These very promising preclinical data justify the use of this new radiopeptide for imaging and potentially internal radiotherapy studies in patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

Similar content being viewed by others

References

  1. Behr TM, Béhé M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999; 43:268–280.

    Google Scholar 

  2. Breeman WAP, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421–1429.

    CAS  PubMed  Google Scholar 

  3. Fischman A, Babich J, Strauss H. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34:2253–2263.

    CAS  PubMed  Google Scholar 

  4. Heppeler A, Froidevaux S, Eberle A, Maecke H. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000; 7:971–994.

    Google Scholar 

  5. Lamberts SW, Van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 25:246–254.

    Article  Google Scholar 

  6. Lister-James J, Moyer B, Dean T. Small peptides radiolabeled with99mTc. Q J Nucl Med 1996; 40:221–233.

    Google Scholar 

  7. Liu S, Edwards D.99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999; 99:2235–2268.

    Article  CAS  PubMed  Google Scholar 

  8. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36:1825–1835.

    CAS  PubMed  Google Scholar 

  9. Thakur M. Radiolabelled peptides: now and the future. Nucl Med Comm 1995; 16:724–732.

    CAS  Google Scholar 

  10. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.

    CAS  PubMed  Google Scholar 

  11. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas—a prospective study. Ann Intern Med 1996; 125:24–26.

    Google Scholar 

  12. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. CHEST 1999; 115:224–232.

    CAS  PubMed  Google Scholar 

  13. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer,99mTc-P829. Cancer Res 1998; 58:1850–1859.

    CAS  PubMed  Google Scholar 

  14. Lebtahi R, Le Cloirec J, Houzard C, et al. Detection of neuroendocrine tumors:99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002; 43:889–895.

    Google Scholar 

  15. de Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368–371.

    Google Scholar 

  16. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DPTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998; 25:668–674.

    Google Scholar 

  17. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90-DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439–1447.

    CAS  PubMed  Google Scholar 

  18. Otte A, Mueller-Brand J, Dellas S, Nitzsche E, Herrmann R, Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417–418.

    CAS  PubMed  Google Scholar 

  19. Cremonesi M, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999; 26:877–886.

    CAS  PubMed  Google Scholar 

  20. Waldherr C, Pless M, Maecke H, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq90Y-DOTATOC. J Nucl Med 2002; 43:610–616.

    Google Scholar 

  21. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with90Y-DOTA-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426–434.

    CAS  PubMed  Google Scholar 

  22. Waldherr C, Pless M, Maecke H, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:942–945.

    Article  Google Scholar 

  23. de Jong M, Breeman WA, Bernard BF, et al. Tumor response after [90Y-DOTA0,Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42:1841–1846.

    Google Scholar 

  24. Reubi J, Schaer J, Waser B, et al. Affinity profiles for human somatostatin receptor sst1–sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273–282.

    CAS  PubMed  Google Scholar 

  25. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28:1319–1325.

    CAS  PubMed  Google Scholar 

  26. Reubi JC, Waser B, Schaer J, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836–846.

    CAS  PubMed  Google Scholar 

  27. Halmos G, Sun B, Schally AV, Hebert F, Nagy A. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab 2000; 85:3509–3512.

    CAS  Google Scholar 

  28. Reubi JC, Schaer J, Waser B, Mengod G. Expression and localization of somatostatin receptor sstr1, sstr2, and sstr3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54:3455–3459.

    CAS  PubMed  Google Scholar 

  29. Forssell-Aronsson E, Nilsson O, Benjegard SA, et al.111In-DTPA-d-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41:636–642.

    Google Scholar 

  30. Raderer M, Pangerl T, Leimer M, et al. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J Nat Cancer Inst 1998; 90:1666–1668.

    CAS  Google Scholar 

  31. Traub T, Petkov V, Ofluoglu S, et al.111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001; 42:1309–1315.

    CAS  PubMed  Google Scholar 

  32. Heppeler A, Froidevaux S, Maecke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999; 5:1974–1981.

    CAS  Google Scholar 

  33. Atherton E, Sheppard R. Fluorenylmethoxycarbonyl-polyamide solid phase peptide synthesis. General principles and development. Oxford: Oxford Information Press, 1989.

  34. Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001; 47:40–53.

    CAS  Google Scholar 

  35. Chiti A, Fanti S, Savelli G, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25:1396–1403.

    Google Scholar 

  36. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853–858.

    Google Scholar 

  37. Cadiot G, Bonnaud G, Lebtahi R, et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 1997; 41:107–114.

    CAS  Google Scholar 

  38. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112:335–347.

    Google Scholar 

  39. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998; 16:1040–1053.

    CAS  Google Scholar 

  40. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10 (Suppl 2):S23–S29.

    Google Scholar 

  41. Janson E, Eriksson B, Oberg K. Treatment with high dose [111In-DTPA-d-Phe1]-octreotide in patients with neuroendocrine tumors. Acta Oncol 1999; 38:373–377.

    PubMed  Google Scholar 

  42. Valkema R, de Jong M, Bakker WH, et al. Phase 1 study of peptide receptor radionuclide therapy with [111In-DTPA0]-octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110–123.

    PubMed  Google Scholar 

  43. de Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA0,Tyr3]Octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628–633.

    PubMed  Google Scholar 

  44. Lewis J, Lewis M, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four64Cu-labeled somatostatin analogues in vitro and in tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1998; 42:1341–1347.

    Article  Google Scholar 

  45. Froidevaux S, Heppeler A, Eberle A, et al. Preclinical comparison in AR4-2J tumor bearing-mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000; 141:3304–3312.

    CAS  PubMed  Google Scholar 

  46. Reubi JC, Eisenwiener KP, Rink H, Waser B, Maecke H. A new peptide somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 456:45–49.

    Article  CAS  PubMed  Google Scholar 

  47. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140:5136–5148.

    Google Scholar 

  48. Maecke H, Scherer G, Heppeler A, Hennig M. Is In-111 an ideal surrogate for Y-90? If not why? Eur J Nucl Med 2001; 28:967.

    Google Scholar 

  49. Eisenwiener KP, Prata MIM, Buschmann I, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconj Chem 2002; 13:530–541.

    CAS  Google Scholar 

  50. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PPA. Fates of endocytosed somatostatin sst2 receptor and associated agonists. Biochem J 1998; 336:291–298.

    CAS  PubMed  Google Scholar 

  51. Raulf F, Pérez J, Joyer D, Bruns C. Differential expression of five somatostatin receptor subtypes, sstr1-5, in the CNS and peripheral tissue. Digestion 1994; 55 (Suppl 3):46–53.

    Google Scholar 

Download references

Acknowledgements

M. Ginj, D. Wild, J. Schmitt and H. Maecke acknowledge support from the Swiss National Science Foundation project No. 31-52969.97, BBW No. C00.0091 and BBT project 4668.1 EUS. The support provided by Novartis Pharma in respect of MS and NMR is gratefully acknowledged.

This work was performed within the COST B12 action.

Author information

Authors and Affiliations

  1. Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland

    Damian Wild, Jörg S. Schmitt, Mihaela Ginj & Helmut R. Mäcke

  2. Department of Nuclear Medicine, University Hospital Rotterdam, 3015 GD, Rotterdam, The Netherlands

    Bert F. Bernard, Eric Krenning & Marion de Jong

  3. Institute of Pathology, University of Bern, 3010, Bern, Switzerland

    Sandra Wenger & Jean-Claude Reubi

Authors
  1. Damian Wild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg S. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mihaela Ginj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helmut R. Mäcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bert F. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marion de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sandra Wenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Claude Reubi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmut R. Mäcke.

Additional information

Abbreviations of the common amino acids are in accordance with the recommendations of IUPAC-IUB [IUPAC-IUB Commission of Biochemical Nomenclature (CBN), Symbols for amino-acid derivatives and peptides, recommendations 1971. Eur J Biochem 1972; 27:201–207].

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wild, D., Schmitt, J.S., Ginj, M. et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30, 1338–1347 (2003). https://doi.org/10.1007/s00259-003-1255-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1255-5

Keywords

Search

Navigation